Media and Feed Optimization in Biotherapeutic Development
How To Guide
Published: September 18, 2025
Credit: Thermo Fisher Scientific
The biotherapeutic manufacturing landscape demands increasingly sophisticated approaches to cell culture optimization, where media selection can make or break product timelines and commercial success.
Many development teams struggle to balance productivity targets, product quality requirements and budget constraints while navigating complex decisions between catalog solutions and custom formulations.
This comprehensive guide provides a strategic framework for optimizing your entire media development workflow, from initial goal-setting through commercial manufacturing scale-up.
Download this guide to learn:
- How to select the best development pathway for your biotherapeutic goals
- Advanced analytics including multi-omics and spent media analysis for optimization
- Best practices for seamless scale-up from research to commercial manufacturing
Media and feed development
A step-by-step guide to workflow optimization
Cell culture
Cell culture media is a foundational component of any biotherapeutic manufacturing
workflow, crucial for maintaining cellular health and viability, maximizing titers, and
supporting high product quality. As such, building a biotherapeutic manufacturing
process with an optimized basal medium and feed system is vital to achieving
optimal results and accelerating the speed-to-market of your product.
However, the process of finding the most suitable basal medium and supplementation
strategy can be challenging, as it requires balancing many key cell culture process
variables to achieve specific technical goals within budget and time constraints.
This guide will provide an insight into each development stage and offer best
practices to help you achieve your project goals on time and within budget.
Optimize every step of your
development workflow
2 thermofisher.com/mediabydesign
Defining your
process goals Prototyping
Manufacturing
Catalog product and
panel screening
Medium development:
key considerations Custom media
development:
analytics and
approaches
Further analytics for
media optimization
Defining your process goals
Before beginning development, it is
important to examine your process and
determine your goals. By comparing these
goals with your internal capabilities and
limitations, you will be able to pinpoint
the solution that is right for you—be that
choosing a catalog option, optimizing a
pre-existing formulation further, or opting
for a completely custom formulation.
The first step will be to clearly define your process goals. These
could be specific productivity targets, such as therapeutic yields,
product quality, or cell health and viability. There may also be
wider project considerations regarding desired timelines and
budgetary constraints. Pre-existing process pain points, such
as process scalability, meeting downstream targets, or other
workflow challenges, could also be addressed through media
development and optimization.
The second step is understanding your capabilities and
limitations. This will help you determine how much development
you can conduct in-house and whether you could benefit from
outsourcing to a third-party media developer. If you do want to
outsource, it will also be important to understand which specific
parts of the process you require support with (for example,
whether you are looking for assistance with minor formulation
adjustments or full formulation development).
Ultimately, your goals will be shaped by the biotherapeutic you
are developing. Different biologics will have different workflows of
varying complexity and resource requirements, all of which affect
the approach you take. For example, innovator and biosimilar
workflows will differ in their cost sensitivity, and recombinant
protein workflows may be more straightforward than those for
cell and gene therapies.
Gibco media insight: The
experienced Gibco™ Media by
Design™ Services team can work
with you to understand your
goals and help design a media
development solution that will
enable you to achieve
bioprocessing success.
3 thermofisher.com/mediabydesign
With your process goals clearly defined and
your capabilities well understood, the next
stage is to find the media solution that is right
for you. Your project timelines, economic
considerations, performance targets, and
process type will all influence your decisions.
In this section, the major factors that should
be considered during this process have
been outlined to help you determine the
most appropriate pathway for your process.
Catalog vs. custom
A significant initial decision is whether you should utilize a catalog
medium, conduct further optimization on a current formulation (if
applicable), or develop a fully custom formulation. This will largely
depend on your project timelines and the internal resources you
can dedicate to media development.
Catalog media and feeds are typically ready-to-use formulations
that can deliver strong yields and consistent product quality off
the shelf within well-established workflows. They can also be
an ideal starting point for further optimization, helping to drive
improved titers and more consistent products without the need
to develop a fully custom medium, which may be beyond the
scope of some projects.
Custom formulations, on the other hand, can be a powerful way
to drive even further improvements. For example, if working with
more established modalities such as monoclonal antibodies
(mAbs), a custom formulation can help improve process
performance and drive an increase in productivity. Additionally,
when working with less established modalities, custom media
might be the only suitable option to help reach challenging
product yield and critical quality attribute (CQA) targets.
Media components and format
The choice of media components can impact culture
performance, so it is important to carefully consider which
ones you want to include in your formulation. Animal origin (AO)
components can come with variability concerns, particularly if not
properly sourced, which may impact process consistency. These
risks can be mitigated through the use of animal origin–free
(AOF) components, effective raw material sourcing and medium
optimization, or a well-understood key component analysis.
Medium development:
key considerations
4 thermofisher.com/mediabydesign
When it comes to the economic feasibility of your process,
some components can add expense. However, their positive
impact on productivity may justify their inclusion. This means
their use often needs to be evaluated on a case-by-case basis
and carefully considered alongside your goals and specific
process requirements.
Choosing your desired media format will also be crucial, as
both liquid and dry format media can be appropriate in different
circumstances. Liquid media comes ready to use, without the
need for reconstitution, but will take up more storage space
compared to the equivalent volume of dry media. This factor
would be particularly important in a perfusion process, which
would likely require significantly larger volumes of media than
a traditional fed-batch workflow. In these instances, it may be
more suitable to opt for a dry format medium to mitigate storage
and shelf-life concerns.
Feeds and feeding strategy
When developing a biotherapeutic manufacturing process, it is
important to pair your basal medium with an appropriate feed
to optimize titers and product quality. Some suppliers may have
feeds specifically tailored to certain media and/or cell lines, which
could help maximize titers and product quality while reducing
initial optimization requirements. Screening multiple feeds to
see which perform best in your specific process is also
worth considering.
Beyond the feeds themselves, feeding strategy should also be
considered. Clones of the same parental cell line can vary in
performance based on the chosen feed strategy, so in order
to maximize process performance, you should consider
the timing and volume of feed addition.
Gibco media insight: The Gibco™
Advanced Granulation Technology
(AGT™) media format is a granular
dry media format that supports
the manufacture of serum-free,
protein-free, and chemically defined
media. Media in the AGT format are
pre-adjusted for pH and osmolality,
offering rapid reconstitution for
increased workflow productivity.
Medium development:
key considerations
5 thermofisher.com/mediabydesign
Off-the-shelf media and feeds can be ideal
starting points for process optimization.
This can be done by screening a variety
of catalog media, feeds, and supplements
to see which deliver the greatest cell
culture performance. For some developers,
this may be all that is required to reach
their goals, and suppliers will often have
dedicated teams available to walk them
through the evaluation process. However,
for those looking to optimize further, a
media or feed panel screening can be
an incredibly useful next step.
Typically, catalog products come with limited formulation
information, making it challenging to set up evaluations that are
truly diverse. In contrast, panels are made up of a selection of
nutritionally diverse formulations designed to help identify key
drivers of cell culture performance, facilitating the identification
of the optimal formulation for a specific target clone.
After completing a panel evaluation, you can utilize more
advanced tools and focus on the components that have the
greatest impact on performance—this is where design of
experiment protocols and analytics can prove useful.
Gibco media insight: Gibco™
media and feed panel evaluations
can help you quickly narrow in on
the components driving increases
in productivity and product quality.
Along with the panel, you have
access to study plans and technical
support to help interpret your
results and decide on next steps.
Catalog product and panel screening
6 thermofisher.com/mediabydesign
Utilizing a custom formulation can be a
powerful way to drive improvements in
performance across a wide range of cell
lines, therapeutic modalities, and process
types. Some of the benefits include
increased productivity, optimized product
quality attributes, removal of undesired
media components, and improvements in
scalability and manufacturability.
Custom media development is typically conducted using a design
of experiments (DOE) protocol. DOE is a statistical method of
setting up experiments that can enable you to predict which
components and interactions are going to have positive or negative
impacts on process performance. This allows you to test a wide
array of different components and concentrations without the
experiment becoming prohibitively large.
The DOE methodology forms the basis of two custom media
development approaches often used in the industry. The first is
a spent media analysis workflow. This iterative approach looks
at the media before, during, and after a bioreactor run to monitor
the utilization of critical components over time. This allows for the
calculation of consumption rates of components, the depletion of
which may be limiting productivity. Once impactful components
are identified, their concentrations can be altered in the formulation
to enhance cell growth and product titers.
The second approach, multi-omics analysis, combines proteomics
and metabolomics to look at additional components—including
around 7,000 proteins and 1,000 metabolites—and provide a more
comprehensive insight into metabolic pathways. Together with
biological data, media analytics, and model statistics, it can help
identify the key components driving productivity. If done correctly,
multi-omics is a powerful tool that can be used to specifically tailor
your formulation to increase the performance of your process and
help you meet your goals.
Custom media development:
analytics and approaches
Gibco media insight: Our media
and feed development services,
which include an advanced
multi-omics workflow, provide a
flexible range of options enabling us
to work with you to deliver scalable
formulations that can help you meet
your product quality and titer goals.
7 thermofisher.com/mediabydesign
There are a wide range of analytical
tests that can be used to investigate cell
culture performance, both during process
optimization and beyond toward commercial
manufacturing. These analyses can help
you make the most of your medium and,
depending on your goals and capabilities,
can be conducted in-house or with an
external organization.
Protein analytics
When developing a biotherapeutic, the quality of the protein
being manufactured is vitally important. CQAs, such as
glycosylation profiles, are crucial for efficacy and patient safety.
From understanding post-translational modifications to verifying
base sequences, it is essential to have the analytical capabilities
and expertise to ensure CQAs are not only being met and
monitored, but also shifted when needed.
Stability testing
Certain media components can be sensitive to degradation. This
can be due to a range of issues, such as interactions with other
components or light sensitivity. The quality of these components
can be monitored over time or through temperature excursions
to verify the robustness of the formulation using stability studies.
Not only can understanding a formulation’s stability help during
development of a manufacturing process, but it can also give you
more confidence in the shelf life of your product. Stability testing
is routine for catalog products; therefore, carrying this out for
custom formulations is equally important.
Investigative analysis
Customized advanced analytical projects can help you
troubleshoot any problems you may be facing in your process.
If you are experiencing variability, a key driver identification
(KDI) approach—using advanced analytical techniques and
mathematical modeling—can be utilized to identify causes of
inconsistent process performance. Additionally, investigative
analytical services can also help address problems including
extractables, leachables, precipitates, and more.
Further analytics for media optimization
Gibco media insight: Gibco™
Media by Design™ Services include a
full suite of bioproduction analyses.
These services can provide powerful
and insightful data that can help
save time and money throughout
your workflow. Our experienced
team of analytical scientists can
help you understand how to get the
most from your cell culture and help
shorten your time to market.
8 thermofisher.com/mediabydesign
To reduce the risk of delays when moving
to commercial manufacturing, it can be
highly beneficial to verify that all formulations
are both manufacturable and scalable.
This can be achieved by leveraging a pilot-scale media prototyping
service. These services replicate the manufacturing process to
rapidly produce small batches of media using cGMP-quality raw
materials and methods. By evaluating the prototype media,
you can accurately assess whether any changes need
to be made to your media formulation before scaling up.
Prototyping can also give you access to further media
manufacturing expertise, helping you add novel components
or remove components not driving cell culture performance.
In preparation for cGMP scale-up, you may also consider
converting your formulation to a different media format to
better suit your scale-up needs and streamline the transition
to large-scale manufacturing.
Gibco media insight: Gibco™
Rapid Prototyping Services
offer small-batch, custom media
manufacturing solutions for research
and process development to
accelerate media development
and scale-up.
Prototyping
9 thermofisher.com/mediabydesign
Once your basal medium and feed
formulations have been finalized, you need
to be able to manufacture them at the scale
required for commercial production of your
biopharmaceutical. This will require choosing
an external vendor with cGMP-validated
manufacturing services—either as your sole
manufacturer or as a secondary supplier.
When choosing and qualifying a vendor, it is vital to fully
evaluate its capabilities and confirm it can meet your specific
requirements. You need to ensure suppliers follow best practices
and have established standard operating procedures to confirm
the quality and identity of raw materials. Confirming the reliability
of its supply chain is also advisable. Evidence of a dependable
supply chain should be provided up front, and establishing a
transparent communication system to share data is critical.
Ultimately, these systems can help identify any potential issues
and streamline your scale-up to large-scale manufacturing.
Gibco media insight: Gibco™
cGMP Media Manufacturing
Services can support your needs
with a worldwide network of
harmonized manufacturing sites.
Our global redundancy helps
provide assurance of supply and
can enable us to meet the lead
times required to help you maintain
consistent production.
Manufacturing
10 thermofisher.com/mediabydesign
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into
humans or animals. © 2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property
of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. EXT4499 0623
Learn more at thermofisher.com/mediabydesign
Working with a media
development collaborator
Developing and optimizing a custom medium and feed
system can be highly beneficial to enhance your workflow for
manufacturing biotherapeutics. However, each step in the
process requires a specific set of skills and capabilities.
External collaborations can enable you to benefit from
next-generation technical capabilities without the need for
investment in new equipment and employee training. You can
also take advantage of knowledge from specialists who have
experience at each development stage.
Leveraging the capabilities and expertise of an external
collaborator can result in accelerated speed-to-market and
help reduce long-term manufacturing risks, enabling you to
successfully deliver your life-changing therapeutic.
Brought to you by
Download the How To Guide for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version